NCT03204578View on ClinicalTrials.gov

Physiological Study of the Human CYP3A Activity (PiSA)

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

September 25, 2017

Study Completion Date

September 25, 2017

Conditions
Cytochrome P450 CYP3A Enzyme Deficiency
Interventions
DRUG

AB (Midazolam OD formulation/Dormicum)

Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd

DRUG

BA (Dormicum/Midazolam OD formulation)

Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd

Trial Locations (1)

4031

University Hospital Basel,, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03204578 - Physiological Study of the Human CYP3A Activity (PiSA) | Biotech Hunter | Biotech Hunter